Rapha Capital Management, LLC, founded in mid-2018, is an investment management firm based in Miami, Florida, specializing in early-stage, non-public biotechnology companies. The firm was established by Dr. Kevin Slawin, an oncologic and robotic surgeon, biotech consultant, investor, and founder, who focuses on disruptive technologies in oncology, T cells, immunotherapy, and other breakthrough healthcare technologies.

Dr. Slawin is also the founder of Bellicum Pharmaceuticals, Inc., a publicly traded company listed on NASDAQ. He has co-invented the FDA-approved "prostate health index (phi)" test, licensed and marketed by Beckman Coulter, and has published extensively in top medical and scientific journals, including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM).

He has been routinely listed in America's Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology.

Rapha Capital Management manages 13 legacy special purpose investment vehicles, Rapha Capital Investment I – XIII, and offers alternative asset management services to the Rapha Capital BioVentures Fund I, LP, which focuses on investments in early-stage life science companies. The firm aims to identify and grow revolutionary ideas in medicine, healthcare, and technology before others can see their value.